Prevention of Stroke by Left Atrial Appendage Closure in Atrial Fibrillation Patients After Intracerebral Hemorrhage

Not Applicable

Active, not recruiting

• Conditions: Stroke; Atrial Fibrillation; Intracerebral Hemorrhage
• Interventions: Device: LAAO; Drug: Medical Therapy

• Registration Number: NCT02830152
• Lead Sponsor: Karolinska Institutet

Brief Summary

Intracerebral hemorrhage (ICH) in patients with non-valvular atrial fibrillation (NVAF) poses a particular dilemma for thromboprophylaxis. Left atrial appendage occlusion (LAAO) is a non-pharmacological approach to prevent cardiac embolism in NVAF. The risk-benefit ratio of LAAO in patients with NVAF after ICH is unknown. The aim of STROKECLOSE is to assess the effect of LAAO to reduce the incidence stroke, bleeding and cardiovascular mortality in patients with NVAF and prior ICH.

Detailed Description

Methods/design: A multicenter prospective randomized open-label clinical trial with blinded outcome evaluation (PROBE design) and blinded safety outcome assessment. The active comparison LAAO is tested against medical therapy in a 2:1 stratified randomization.

Study population: Patients should have had an ICH within 12 months prior to enrollment and have NVAF with increased risk of stroke or systemic embolism, as indicated by a CHA2DS2VASc score \>2. In total 750 patients will be included. Active enrollment ensues over 3 years followed by 5 years follow-up and a long-term follow-up at 10 years.

Intervention and control: The intervention group will be treated by LAAO, using the Amplatzer Amulet device. Implantation requires a catheterization procedure using venous access and transseptal puncture and is guided by angiography, fluoroscopy and transesophageal echocardiography (TEE) or intracardiac echocardiography (ICE). Recommended post-implant antithrombotic therapy includes aspirin (ASA) therapy for at least 6 months, with or without clopidogrel for the first 45 days after implantation. The control group will receive medical therapy, delivered according to national standards and guidelines at the treating physicians' discretion. This may include oral anticoagulation (OAC) (vitamin-K antagonists, VKA), non-VKA OAC, antiplatelet therapy or no antithrombotic therapy at all.

Main study outcomes: The primary outcome is the composite endpoint of stroke (ischemic and hemorrhagic), systemic embolism, life-threatening or major bleeding and all-cause mortality, assessed over at least two years. Secondary outcome examines various early and late safety outcome parameters.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2016-06-29
• Study First Submitted QC: 2016-07-08
• Study First Posted: 2016-07-12
• Study Start: 2017-05-03
• Status Verified: 2024-06
• Last Update Submitted: 2024-06-11
• Last Update Posted: 2024-06-12
• Primary Completion: 2027-12
• Study Completion: 2028-12

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 750

Inclusion Criteria

• A diagnosis of paroxysmal, persistent or long-standing NVAF with CHA2DS2VASc score >2.
• Clinical and CT/MRI evidence of ICH within 12 months but not less than 4 weeks prior to enrollment.
• Age > 18 years.
• Signed informed consent.

Read More

Exclusion Criteria

• ICH secondary to vascular malformation or tumors
• Estimated life expectancy of less than 1 year at eligibility assessment
• mRS > 3 at enrollment
• Prior surgical LAA excision
• Planned combined interventional procedures at the time of enrollment

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Left Atrial Appendage Occlusion (LAAO)	LAAO	The intervention is implantation of Amplatzer Amulet LAAO device within two months after randomization. Device implantation comprises a catheterization procedure using venous access and a transseptal puncture to obtain access to the left atrium (LA). Procedural imaging guidance is left to the physician's discretion and may include several techniques such as angiography/fluoroscopy, transesophageal echocardiography (TEE) and/or intracardiac echocardiography (ICE). Recommended post-implant antithrombotic therapy includes ASA therapy for at least 6 months, which may be combined with clopidogrel for the first 45 days after implantation.
Medical Therapy	Medical Therapy	The optimal medical therapy of stroke prevention in non-valvular atrial fibrillation (NVAF) after intracerebral hemorrhage (ICH) is not known. Therefore, it will be left to the discretion of the treating physician to decide if, when, and which pharmacological therapy will be prescribed. Available options include anticoagulation with oral anticoagulation (OAC) or novel oral anticoagulants (NOAC), antiplatelet therapy (including monotherapy and dual antiplatelet therapy) and no pharmacological antithrombotic therapy.

Primary Outcome Measures

Name	Time	Method
Composite endpoint of stroke (ischemic or hemorrhagic), systemic embolism, life-threatening or major bleeding and all-cause mortality	up to 5 years after randomization	This endpoint will be assessed in patients with paroxysmal, persistent or long-standing NVAF and with ICH within 6 months prior to enrollment.; The effect of LAAO will be compared to medical therapy at the treating physician's discretion as a control.

Secondary Outcome Measures

Name	Time	Method
Number of participants with a device-related complication	up to 45 days after randomization	A complication related to the presence of the device. Device-related complications include: * Device embolization; * Device erosion; * Clinically significant device interference with surrounding structures. This includes structures at the implant location (circumflex coronary artery, mitral valve, pulmonary artery, pulmonary vein) or cardiovascular structures in the vicinity of the location to which the device migrated (if applicable).; * Device thrombus; * Device fracture; * Device infection/endocarditis/pericarditis; * Device perforation/laceration; * Device allergy
Number of Participants with a device success	up to 45 days after randomization	Device deployed and implanted in correct position.
Number of Participants with a Technical success	up to 45 days after randomization	Exclusion of the left atrial appendage (LAA) achieved without device-related complications and no leak \>5 mm on color Doppler TEE.
Number of Participants with a Procedural success	up to 45 days after randomization	Technical success and no procedure-related complications, except uncomplicated device embolization (i.e. device embolization resolved by percutaneous retrieval during the procedure without surgical intervention or damage to surrounding cardiovascular structures).
Number of Participants with Significant peridevice leak	up to 45 days after randomization	Consistent with the definition of technical success, a significant peridevice leak is defined as a leak shown as a jet \>5 mm on color Doppler TEE.
Compare the functional status prior to and post treatment	24 months after randomization	The Modified Rankin Scale (mRS) will be used for measuring the Functional status.
Compare the cognitive status prior to and post treatment	24 months after randomization	The cognitive status will be assessed by using Montreal Cognitive Assessment (MOCA) and Mini-mental state examination (MMSE)
Compare the neurological status prior to and post treatment	24 months after randomization	The National Institutes of Health Stroke Scale (NIHSS) is used to assess the neurological status
Compare the quality of life prior to and post treatment by using EuroQol	24 months after randomization	EuroQol assesses health status in terms of five dimension: mobility (walking about); looking after myself; doing usual activities (e.g., going to school, hobbies, sports, playing, doing things with family and friends); having pain or discomfort; and feeling worried, sad, or unhappy. The levels for the dimensions are: 'none/no problems', 'some (problems)', and 'a lot (of problems)'. Higher score represents more problems.
Late safety outcome parameters of LAAO and Medical therapy	up to 10 years after randomization	Stroke (ischemic or hemorrhagic), systemic embolism, bleeding, all-cause mortality, intracranial hemorrhage, cardiovascular mortality and unplanned hospitalization will be evaluated

Trial Locations

Locations (17)

Turku University Hospital; 🇫🇮 Turku, Finland

Vaasa Centralsjukhus; 🇫🇮 Vaasa, Finland

Haukeland Universitetssjukhus; 🇳🇴 Bergen, Norway

Universitetssjukhuset Skåne; 🇸🇪 Lund, Sweden

Helsinki University Hospital; 🇫🇮 Helsinki, Finland

Oslo University Hospital; 🇳🇴 Oslo, Norway

Sahlgrenska University Hospital; 🇸🇪 Göteborg, Sweden

North Karelia Central Hospital; 🇫🇮 Joensuu, Finland

Danderyd Hospital; 🇸🇪 Stockholm, Sweden

Akademiska sjukhuset; 🇸🇪 Uppsala, Sweden

Odenses Universitetssjukhus; 🇩🇰 Odense, Denmark

Bispebjerg University Hospital; 🇩🇰 Bispebjerg, Denmark

Rikshospitalet Glostrup; 🇩🇰 Glostrup, Denmark

Aarhus University Hospital; 🇩🇰 Aarhus, Denmark

Kuopio University Hospital; 🇫🇮 Kuopio, Finland

Herlev sjukhus; 🇩🇰 Herlev, Denmark

Universitetssjukhuset; 🇸🇪 Örebro, Sweden